Fujita Health University Nanakuri Sanatorium, 424-1 Odoricho, Tsu, Mie, 514-1295, Japan.
Oncologist. 2010;15(7):750-9. doi: 10.1634/theoncologist.2010-0054. Epub 2010 Jun 29.
We conducted a systematic review and meta-analysis to better define the prognostic ability of fluorine-18-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) following salvage chemotherapy for relapsed or refractory Hodgkin's lymphoma (HL) and aggressive non-Hodgkin's lymphoma.
We searched PubMed (from inception to January 31, 2010), bibliographies, and review articles without language restriction. Two assessors independently assessed study characteristics, quality, and results. We performed a meta-analysis to determine prognostic accuracy.
Twelve studies including 630 patients were eligible. The most commonly evaluated histologies were diffuse large B-cell lymphoma (n = 313) and HL (n = 187), which were typically treated with various salvage and high-dose chemotherapy regimens. Studies typically employed nonstandardized protocols and diagnostic criteria. The prognostic accuracy was heterogeneous across the included studies. (18)F-FDG PET had a summary sensitivity of 0.69 (95% confidence interval [CI], 0.56-0.81) and specificity of 0.81 (95% CI, 0.73-0.87). The summary estimates were stable in sensitivity analyses. In four studies that performed direct comparisons between PET and conventional restaging modalities, PET had a superior accuracy for predicting treatment outcomes. Subgroup and metaregression analyses did not identify any particular factor to explain the observed heterogeneity.
(18)F-FDG PET performed after salvage therapy appears to be an appropriate test to predict treatment failure in patients with refractory or relapsed lymphoma who receive high-dose chemotherapy. Some evidence suggests PET is superior to conventional restaging for this purpose. Given the methodological limitations in the primary studies, prospective studies with standardized methodologies are needed to confirm and refine these promising results.
我们进行了一项系统评价和荟萃分析,以更好地定义氟-18-氟代脱氧葡萄糖正电子发射断层扫描((18)F-FDG PET)在挽救性化疗后复发或难治性霍奇金淋巴瘤(HL)和侵袭性非霍奇金淋巴瘤患者中的预后能力。
我们无语言限制地检索了 PubMed(从创建到 2010 年 1 月 31 日)、参考文献和综述文章。两位评估员独立评估了研究特征、质量和结果。我们进行了荟萃分析以确定预后准确性。
12 项研究共纳入 630 例患者。最常评估的组织学类型为弥漫性大 B 细胞淋巴瘤(n = 313)和 HL(n = 187),这些患者通常接受各种挽救性和高剂量化疗方案治疗。研究通常采用非标准化方案和诊断标准。纳入研究的预后准确性存在异质性。(18)F-FDG PET 的汇总敏感性为 0.69(95%置信区间 [CI],0.56-0.81),特异性为 0.81(95% CI,0.73-0.87)。敏感性分析中汇总估计值稳定。在四项直接比较 PET 与常规重新分期方法的研究中,PET 对预测治疗结果具有更高的准确性。亚组和荟萃回归分析未发现任何特定因素可以解释观察到的异质性。
在接受高剂量化疗的难治性或复发性淋巴瘤患者中,挽救性治疗后进行 (18)F-FDG PET 似乎是预测治疗失败的合适检查方法。有一些证据表明 PET 在这方面优于常规重新分期。鉴于原始研究中的方法学局限性,需要进行具有标准化方法的前瞻性研究来证实和完善这些有前途的结果。